| Naslov: | Lung cancer biomarker testing : perspective from Europe |
|---|
| Avtorji: | ID Thunnissen, Erik (Avtor)
ID Weynand, Birgit (Avtor)
ID Udovicic-Gagula, Dalma (Avtor)
ID Brčić, Luka (Avtor)
ID Szolkowska, Malgorzata (Avtor)
ID Hofman, Paul (Avtor)
ID Smojver-Ježek, Silvana (Avtor)
ID Anttila, Sisko (Avtor)
ID Calabrese, Fiorella (Avtor)
ID Kern, Izidor, Klinika Golnik (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1,80 MB)
MD5: 08500071FD4E2273A0DACAEECA7E7FDB
 URL - Izvorni URL, za dostop obiščite http://tlcr.amegroups.com/article/view/40413/pdf
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.02 - Pregledni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future. |
|---|
| Ključne besede: | lung neoplasms -- diagnosis -- therapy -- Europe, lung cancer, predictive testing |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Kraj izida: | Kitajska |
|---|
| Založnik: | AME Publishing |
|---|
| Leto izida: | 2020 |
|---|
| Št. strani: | str. 887-897 |
|---|
| Številčenje: | Vol. 9, iss. 3 |
|---|
| PID: | 20.500.12556/DiRROS-12421  |
|---|
| UDK: | 616-006 |
|---|
| ISSN pri članku: | 2226-4477 |
|---|
| COBISS.SI-ID: | 28071683 |
|---|
| Avtorske pravice: | © Translational Lung Cancer Research |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Soavtor iz Slovenije: Izidor Kern;
Opis vira z dne 11. 9. 2020;
|
|---|
| Datum objave v DiRROS: | 21.09.2020 |
|---|
| Število ogledov: | 2201 |
|---|
| Število prenosov: | 1232 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
